---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026715"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:12:57.937225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera Q4 revenue $217.3M (+25.6% YoY); net loss $142.6M; guides 2023 rev $980M-$1B

## Summary
- Q4 total revenue $217.3M (+25.6% YoY); product revenue $212.9M (+28.2%); tests processed 559,700 (+27.6%).
- Full-year 2022 revenue $820.2M (+31.1% YoY); net loss $547.8M ($5.57/diluted) vs $471.7M ($5.21) in 2021.
- Oncology tests 196,000 in 2022 (+158% YoY); 40 peer-reviewed studies for Signatera published.
- 2023 guidance: revenue $980M-$1B; gross margin 41%-44%; net cash consumption $300M-$325M.
- Appointed Ruth Williams-Brinkley to board effective March 2, 2023.

## SEC filing metadata
- accession: 0001104659-23-026715
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465923026715/0001104659-23-026715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465923026715/tm238033d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026715
- JSON: https://secwatch.observer/filing/0001104659-23-026715.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.